Board/Management Information • Mar 19, 2014
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 19 March 2014 15:30
STRATEC – Chief Sales Officer to leave company
STRATEC Biomedical AG / Key word(s): Change of Personnel
19.03.2014 / 15:30
STRATEC – Chief Sales Officer to leave company
Birkenfeld, March 19, 2014
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announces that Bernd M. Steidle (Member, Board of Management, Marketing and Sales) has left the Board of Management as of March 19, 2014 and will have no further involvement in the company’s operations.
The Supervisory Board and Board of Management of STRATEC would like to thank Mr. Steidle for his longstanding commitment and significant achievements on behalf of STRATEC and wishes him all the best in his future endeavours.
Company structures in the fields of marketing and sales will now be realigned under the management of company CEO Marcus Wolfinger. In future, the responsibilities for marketing and sales will be managed at senior vice president level. There are no plans to appoint a new member of the Board of Management with responsibility for sales and marketing in the near future.
About STRATEC
STRATEC Biomedical AG ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
End of Corporate News
19.03.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | STRATEC Biomedical AG |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE0007289001 |
| WKN: | 728900 |
| Indices: | TecDAX |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 258398 19.03.2014 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.